RSS

opioid addiction

Public Health England (PHE) has launched an opioid treatment quality improvement programme where it will work with drug treatment providers and service users to develop tools to improve opioid substitution treatment. more

News

Global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, Catalent Pharma Solutions, has entered into a commercial manufacturing agreement with US WorldMeds for lofexidine. more

News

Indivior, a speciality pharmaceutical company, has opened a $30 million research and development (R&D) centre in Hull, UK, to further advance its treatment innovation into the global addiction crisis. more

News

With patient adherence and prevention of overdose hot topics for pharma, regulatory and healthcare sectors, the rise of implants for the sustained and controlled delivery of drugs is perhaps an inevitable trend. more

Opinion

Lucideon and Skyepharma sign an exclusive feasibility, development and licence agreement to provide Skyepharma’s oral business with access to Lucideon’s proprietary abuse deterrent controlled release technology, iCRT-deter more

News

The Psychopharmacologic Drugs Advisory Committee (PDAC) of the US Food and Drug Administration (FDA) has voted in favour of approving Probuphine, an implant to treat opioid addiction more

News